scholarly journals Current Drugs with Potential for Treatment of COVID-19: A Literature Review

2020 ◽  
Vol 23 (1) ◽  
pp. 58-64 ◽  
Author(s):  
Md Insiat Islam Rabby
Keyword(s):  
Clinical Trial ◽  
Severe Acute Respiratory Syndrome ◽  
Laboratory Tests ◽  
Literature Search ◽  
Treatment Process ◽  
Clinical Use ◽  
Animal Trial ◽  
Chinese Drugs ◽  
Inflammatory Drugs ◽  
Traditional Chinese Drugs

Purpose: SARS-CoV-2 first emerged in China in December 2019 and rapidly spread worldwide. No vaccine or approved drug is available to eradicate the virus, however, some drugs that are indicated for other afflictions seems to be potentially beneficial to treat the infection albeit without unequivocal evidence.   The aim of this article is to review the published background on the effectiveness of these drugs against COVID-19 Methods: A thorough literature search was conducted on recently published studies which have published between January 1 to March 25, 2020. PubMed, Google Scholar and Science Direct databases were searched Results: A total 22 articles were found eligible. 8 discuss about treatment outcomes from their applied drugs during treatment of COVID-19 patients, 4 report laboratory tests, one report animal trial and other 9 articles discuss recommendations and suggestions based on the treatment process and clinical outcomes of other diseases such as malaria, ebola, severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). The data and/or recommendations are categorized in 4 classes: (a) anti-viral and anti-inflammatory drugs, (b) anti-malaria drugs, (c) traditional Chinese drugs and (d) other treatments/drugs. Conclusion: All examined treatments, although potentiality effective against COVID-19, need either appropriate drug development or clinical trial to be suitable for clinical use.

Critical limb ischaemia in diabetes: definition, assessment, prognosis

VASA ◽  
2001 ◽  
Vol 30 (Supplement 58) ◽  
pp. 21-27
Author(s):  
Luther
Keyword(s):  
Diabetic Foot ◽  
Laboratory Tests ◽  
Critical Limb Ischaemia ◽  
Limb Ischaemia ◽  
Clinical Use ◽  
Arterial Reconstruction ◽  
Arterial Circulation ◽  
Diabetic Foot Disease ◽  
Foot Disease ◽  
Fontaine Classification

In diabetic foot disease, critical limb ischaemia (CLI) cannot be precisely described using established definitions. For clinical use, the Fontaine classification complemented with any objective verification of a reduced arterial circulation is sufficient for decision making. For scientific purposes, objective measurement criteria should be reported. Assessment of CLI should rely on the physical examination of the limb arteries, complemented by laboratory tests like the shape of the PVR curve at ankle or toe levels, and arteriography. The prognosis of CLI in diabetic foot disease depends on the success of arterial reconstruction. The best prognosis for the patients is with a preserved limb. Reconstructive surgery is the best choice for the majority of patients.

Recognition on toxicity of traditional Chinese drugs

2003 ◽  
Vol 1 (4) ◽  
pp. 252-254 ◽  
Author(s):  
Chao-Qin Yu
Keyword(s):  
Chinese Drugs ◽  
Traditional Chinese Drugs

scholarly journals Quality control of traditional chinese drugs by high performance liquid chromatography.

1986 ◽  
Vol 35 (3) ◽  
pp. 202-206 ◽  
Author(s):  
Nobuyuki HITOMI ◽  
Kesamitsu SHIMIZU ◽  
Keiichi YAMAMOTO ◽  
Osamu MIURA ◽  
Eizaburo YUMIOKA
Keyword(s):  
Quality Control ◽  
High Performance Liquid Chromatography ◽  
Liquid Chromatography ◽  
High Performance ◽  
Chinese Drugs ◽  
Traditional Chinese Drugs

Practical Aspects of Implementing and Applying Health Care Cloud Computing Services and Informatics to Cancer Clinical Trial Data

2021 ◽  
pp. 826-832
Author(s):  
Jay G. Ronquillo ◽  
William T. Lester
Keyword(s):  
Health Care ◽  
Clinical Trial ◽  
Cancer Research ◽  
Cloud Computing ◽  
Clinical Trials ◽  
Laboratory Tests ◽  
Cancer Clinical Trial ◽  
Cancer Clinical Trials ◽  
Precision Oncology ◽  
Oncology Research

PURPOSE Cloud computing has led to dramatic growth in the volume, variety, and velocity of cancer data. However, cloud platforms and services present new challenges for cancer research, particularly in understanding the practical tradeoffs between cloud performance, cost, and complexity. The goal of this study was to describe the practical challenges when using a cloud-based service to improve the cancer clinical trial matching process. METHODS We collected information for all interventional cancer clinical trials from ClinicalTrials.gov and used the Google Cloud Healthcare Natural Language Application Programming Interface (API) to analyze clinical trial Title and Eligibility Criteria text. An informatics pipeline leveraging interoperability standards summarized the distribution of cancer clinical trials, genes, laboratory tests, and medications extracted from cloud-based entity analysis. RESULTS There were a total of 38,851 cancer-related clinical trials found in this study, with the distribution of cancer categories extracted from Title text significantly different than in ClinicalTrials.gov ( P < .001). Cloud-based entity analysis of clinical trial criteria identified a total of 949 genes, 1,782 laboratory tests, 2,086 medications, and 4,902 National Cancer Institute Thesaurus terms, with estimated detection accuracies ranging from 12.8% to 89.9%. A total of 77,702 API calls processed an estimated 167,179 text records, which took a total of 1,979 processing-minutes (33.0 processing-hours), or approximately 1.5 seconds per API call. CONCLUSION Current general-purpose cloud health care tools—like the Google service in this study—should not be used for automated clinical trial matching unless they can perform effective extraction and classification of the clinical, genetic, and medication concepts central to precision oncology research. A strong understanding of the practical aspects of cloud computing will help researchers effectively navigate the vast data ecosystems in cancer research.

scholarly journals Clinical Use of a Prediction Rule to Guide Admission Policy in Community-Acquired Invasive Urinary Tract Infection: A Randomized Clinical Trial

2015 ◽  
Vol 2 (suppl_1) ◽  
Author(s):  
J.E. Stalenhoef ◽  
C. Van Nieuwkoop ◽  
A. M. Vollaard ◽  
W. E. Van Der Starre ◽  
N. M. Delfos ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Urinary Tract Infection ◽  
Urinary Tract ◽  
Tract Infection ◽  
Randomized Clinical Trial ◽  
Prediction Rule ◽  
Admission Policy ◽  
Clinical Use

Book Review: Nonsteroidal Anti-Inflammatory Drugs: Mechanisms and Clinical Use

DICP ◽  
1990 ◽  
Vol 24 (9) ◽  
pp. 895-896
Author(s):  
Stephen L. Dahl
Keyword(s):  
Clinical Use ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

scholarly journals Pharmacotherapy in Oral and Maxillofacial Surgery

2021 ◽  
pp. 195-215
Author(s):  
Latha P. Rao
Keyword(s):  
Literature Search ◽  
Maxillofacial Surgery ◽  
Medical Professionals ◽  
Oral And Maxillofacial Surgery ◽  
Pharmacological Properties ◽  
Review Of Literature ◽  
Surgical Practice ◽  
Inflammatory Drugs ◽  
Prescribed Medicines ◽  
Anti Inflammatory

AbstractThe field of pharmacology has always fascinated medical professionals—the ability to cure a disease by prescribing medicine is very tempting. Medical and surgical specialties benefit from the correct use of drugs, and oral and maxillofacial surgery (OMFS) is no exception. Antibiotics, analgesics, and anti-inflammatory drugs are among commonly prescribed medicines in a maxillofacial surgical practice. Umpteen number of literature studies are available on the usage of these medicines in maxillofacial surgery. A review of literature is attempted in this chapter to reach a consensus in matters pertaining to these drugs. The task was in no way an easy one as no two studies compared the same group of medicines or similar pharmacological properties. The key facts, which have emerged from this literature search, have been projected in this chapter.

scholarly journals ‘Dry’ Pericarditis with Rapid Progression to Tamponade as a Feature of COVID-19

2021 ◽  
Author(s):  
Ashwin Reddy ◽  
Sarah Nethercott ◽  
Rudolph Duehmke ◽  
Sunil Nair ◽  
Omar Abdul-Samad
Keyword(s):  
Pericardial Effusion ◽  
Severe Acute Respiratory Syndrome ◽  
Stable Condition ◽  
Full Recovery ◽  
Rapid Progression ◽  
Life Threatening ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

Pericardial inflammation is a recognised feature of coronavirus disease (COVID-19). The authors herein present the case of a female with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection who developed a large and life-threatening pericardial effusion over a few days following the onset of pericarditis, despite prompt commencement of treatment. This was successfully drained, and she was discharged in stable condition on oral nonsteroidal anti-inflammatory drugs and colchicine.At 6-week follow-up she had made a full recovery, and repeat echocardiography demonstrated no recurrence of effusion or evidence of constrictive physiology.

scholarly journals Facing the SARS-CoV-2 Outbreak: What Should Obstetricians and Gynecologists Do?

2020 ◽  
Vol 14 (4) ◽  
pp. e19-e21
Author(s):  
Hongyuan Zhang ◽  
Yuanjing Hu ◽  
Yingjun Zhu ◽  
Xu Chen
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
North China ◽  
Treatment Process ◽  
Diagnosis And Treatment ◽  
Obstetrics And Gynecology ◽  
Special Group ◽  
Key Points ◽  
Major Outbreak ◽  
Available Information

ABSTRACTAn outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide. In this major outbreak, women are a special group, especially pregnant patients. Many problems faced by clinicians are still unclear and need to be solved. As the largest obstetrics and gynecology hospital in North China, here we summarize the diagnosis and treatment process and key points of obstetrics and gynecology patients in our hospital during the period of the COVID-19 pandemic, hoping to provide available information to inform care of obstetrics and gynecology patients.

Sign in / Sign up

Export Citation Format

Share Document